The BRAF inhibitors vemurafenib, dabrafenib and encorafenib are used in the treatment of
patients with BRAF-mutant melanoma. They selectively target BRAF kinase and thus …

Abstract Purpose of Review As cancer remains an increasing problem in industrial
countries, the incidence of melanoma has risen rapidly in many populations during the last …

The NCCN Guidelines for Colon Cancer provide recommendations regarding diagnosis,
pathologic staging, surgical management, perioperative treatment, surveillance …

Simple Summary Immunotherapies and molecularly targeted therapies have drastically
changed the therapeutic approach for unresectable advanced or metastatic melanoma. The …

Purpose: Mitogen-activates protein kinase (MAPK) inhibitors, particularly MEK inhibitors,
have shifted the treatment paradigm for metastatic BRAF-mutant cutaneous melanoma; …

Multiple genetic mutations within melanoma not only cause lesion-specific responses to
targeted therapy but also alter the molecular route of resistance to that therapy. Inactivation …

Melanoma is the most fatal skin cancer. In the early stages, it can be safely treated with
surgery alone. However, since 2011, there has been an important revolution in the treatment …

Despite the considerable progress in understanding the biology of human cancer and
technological advancement in drug discovery, treatment failure remains an inevitable …

RAS pathway mutations have been linked to relapse and chemotherapy resistance in
pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However …

The treatment landscape in advanced melanoma is changing dramatically with the approval
of new drugs. Vemurafenib was the first approved targeted agent for the treatment of BRAF …